Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Limited benefits from antivirals in Bell’s palsy
Vault Navigation
Limited benefits from antivirals in Bell’s palsy
How effective are antiviral treatments alone, or in combination with other therapy, for Bell’s palsy?
Moderate-quality evidence from randomised controlled trials showed no additional benefit from the combination of antivirals with corticosteroids, compared to corticosteroids alone, for the treatment of Bell's palsy of various degrees of severity. There was a small but just significant benefit of combination therapy, compared with corticosteroids alone, in severe Bell’s palsy. Corticosteroids alone were more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo or no treatment. There was no benefit from antivirals alone over placebo. The combination of antivirals and corticosteroids reduced sequelae of Bell's palsy (excessive tear production and synkinesis) compared with corticosteroids alone. There was no significant increase in adverse events from the use of antivirals compared with either placebo or corticosteroids.
There were insufficient data to examine any of the other variables reported in the studies, such as pain, quality of life, and variation in response due to time to treatment and severity at onset.
Corticosteroids are widely used in the treatment of Bell’s palsy, but the effectiveness of additional treatment with an antiviral agent is uncertain.
Gagyor I et al. Antiviral treatment for Bell’s palsy (idiopathic facial palsy). Cochrane Reviews, 2015, Issue 7. Art. No.: CD001869.DOI: 10.1002/14651858. CD001869.pub6. This review contains 11 studies involving 2,883 participants.
Cochrane Systematic Reviews for primary care practitioners
Developed by the Cochrane Primary Care Field, New Zealand Branch of the Australasian Cochrane Centre at the Department of General Practice and Primary Health Care, University of Auckland and funded by the Ministry of Health and New Zealand Doctor. PEARLS are meant for educational use and not to guide clinical care. New Zealanders can access the Cochrane Library free via www.cochrane.org.nz